OSE Immunotherapeutics to Present Groundbreaking Extension Period
Data on Lusvertikimab at DDW 2025
New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term
Benefits and Safety of Anti-IL-7R mAb Lusvertikimab

NANTES, France – April 9, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN:
FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class
therapies in immuno-oncology and immuno-inflammation, today announced that the
Company will present further efficacy and safety data1 from the 24-week Open Label
Extension (OLE) period from CoTikiS Phase 2 clinical study of Lusvertikimab in ulcerative colitis
at the Digestive Disease Week conference in San Diego (May 3 – 6, 2025).
Following the excellent efficacy and safety profile from the trial’s induction period presented
as a highlight at the 2025 ECCO congress, this oral presentation will unveil new clinical data
from the 24-week Open Label Extension (OLE) period (Week 10 to Week 34) of the
randomized, double-blind, placebo-controlled Phase 2 study evaluating the anti-IL-7 receptor
monoclonal antibody Lusvertikimab in moderate to severe ulcerative colitis. These new
findings are expected to provide deeper insights into the long-term benefits and safety of
Lusvertikimab, supporting further development in ulcerative colitis, as well as in other chronic
autoimmune and inflammatory diseases.
Presentation details:
Title: “LUSVERTIKIMAB, A FIRST IN CLASS IL7 RECEPTOR ANTAGONIST, IN MODERATE TO SEVERE
ULCERATIVE COLITIS: RESULTS OF A MULTICCENTER RANDOMIZED PLACEBO-CONTROLLED PHASE II
STUDY”

Date and Time: Monday, May 05, 2025, from 4:45pm to 5:00pm Pacific Time
Session Presentation: Clinical Trials in IBD: Biologics and Emerging Therapies
Session Number: 0004

ABOUT ULCERATIVE COLITIS (UC)
Ulcerative colitis is a chronic disease of the large intestine, or colon, and rectum, in which the lining of the
gastrointestinal tract becomes inflamed and develops ulcers. This condition is the result of an overactive
immune system. UC affects 3.3 million patients in the US, Europe and Japan2. Despite broad therapeutic
options, remission rates are only 25-30%3 leaving most patients without satisfactory treatments. 15% of
patients4 fail to respond to all therapies and undergo surgery as a last option.


1 The abstract was submitted before the completion of the 24-week Open Label Extension (OLE) period. The new data to be presented at
DDW 2025 includes additional findings not available at the time of submission.
2 Evaluate Pharma
3
Drugs Context. 2019; 8: 212572 –doi: 10.7573/dic.212572
4
Scientific Reports volume 10, Article number: 12546 (2020)


1
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology
(IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner
with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the
market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between
Nantes and Paris and is quoted on Euronext.

Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-
immuno.com. Click and follow us on LinkedIn.




Contacts
Fiona Olivier French Media Contact
fiona.olivier@ose-immuno.com FP2COM
Florence Portejoie
Sylvie Détry fportejoie@fp2com.fr
sylvie.detry@ose-immuno.com +33 6 07 768 283

U.S. Media Contact
Rooney Partners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking
information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based upon certain assumptions and assessments made
by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current
economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”,
“anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are
reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such
expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally
beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially
from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or
identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance. This press release includes only summary information and should be read with the OSE
Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial
report for the fiscal year 2023, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law,
OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or
revise the forward-looking information or statements.




2